Increased Demand Causes Fuji to Expand Astaxanthin Production
The plan is to double current production capacity.
Fuji Chemical Industry Company, Ltd., (Toyama, Japan) announced plans to double production of its AstaReal natural astaxanthin (Haematococcus pluavialis) in response to increased demand worldwide, the company says. Production will ramp up at Fuji’s wholly owned subsidiary BioReal AB in Gustavsberg, Sweden.
The company says demand has been driven by increasing science supporting AstaReal’s “positive effects on health,” along with AstaReal’s GRAS approval in the United States last year.
The company says that production at the BioReal facility can be expanded rapidly. The plan is to double current production capacity.
The Nutritional Outlook Podcast Episode 33: Keeping up with contract manufacturing
July 26th 2024Nutritional Outlook talks to Lauren Samot, commercial innovation leader, and Blayney McEneaney, sales executive at Vitaquest International, about trends within the contract manufacturing space, and the ways in which contract manufacturers like Vitaquest keep up with the market and differentiate themselves from the competition.
